RegulatoryCompany release

Scancell's melanoma DNA vaccine iSCIB1+ gets FDA RMAT designation ahead of Phase 3

Scancell Holdings plc · Thu 19 Nov 2026

The US regulator has added RMAT status to iSCIB1+ for advanced melanoma, which already holds Fast Track, as Scancell prepares to dose the first Phase 3 patient in December.

Scancell Holdings said on 19 November 2026 that the US Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to iSCIB1+ for advanced melanoma. The DNA vaccine, which now has the agreed WHO international nonproprietary name inzitagene plasmivec, already held Fast Track status.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release: Scancell Holdings plc ↗

Article written by VigiEye from the official source (Scancell Holdings plc). Claims are the company's own. AI-assisted; check the source before acting.